Cardinal Health超越第三季度财报，上调2026年指引，股价于2025年11月23日上涨至209.27美元。 Cardinal Health beat Q3 earnings, raised 2026 guidance, and its stock rose to $209.27 on Nov. 23, 2025.

在2025年第二季度,一些机构投资者调整了他们对卡迪纳尔健康公司 (CAH) 的股权,TD Waterhouse Canada,瑞士国家银行和Handelsbanken Fonder AB增加了他们的持有权,而Vestor Capital LLC则减少了78.5%的持有权. In the second quarter of 2025, several institutional investors adjusted their stakes in Cardinal Health, Inc. (CAH), with TD Waterhouse Canada, the Swiss National Bank, and Handelsbanken Fonder AB increasing their holdings, while Vestor Capital LLC reduced its position by 78.5%. 该公司于10月30日报告Q3收入丰厚, 公布2.55 EPS(超额估计)和64.01亿美元收入, 比上一年增长22.4%。 The company reported strong Q3 earnings on October 30, posting $2.55 EPS—surpassing estimates—and $64.01 billion in revenue, up 22.4% year-over-year. 卡迪纳尔健康公司将其2026财年的每股收益指导提高到9.65美元9.85美元,并保持了206.57美元的目标价格的共识"中等购买"评级. Cardinal Health raised its fiscal 2026 EPS guidance to $9.65–$9.85 and maintains a consensus "Moderate Buy" rating with a target price of $206.57. 2025年11月23日的股票交易额为209.27美元,市场上限为497.2亿美元,P/E比率为32.45。 The stock traded at $209.27 on November 23, 2025, with a market cap of $49.72 billion and a P/E ratio of 32.45.